to risiko for ledekateter- trombose hos patienter, der gennemgår PCI og behandles med fondaparinux som antikoagulans.
Incidences in non-primary PCI in UA/ NSTEMI were 1.0% vs 0.3% (fondaparinux vs. enoxaparin) and in primary PCI in STEMI were